Advanced search
1 file | 502.61 KB Add to list

Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer

(2018) GYNECOLOGIC ONCOLOGY. 150(3). p.446-450
Author
Organization
Keywords
Epithelial ovarian cancer, Primary debulking surgery, Neoadjuvant chemotherapy, Adjuvant chemotherapy, Timing, Overall survival, TIME-INTERVAL, NEOADJUVANT CHEMOTHERAPY, PROGNOSTIC IMPORTANCE, COMORBIDITY INDEX, CLINICAL-PRACTICE, INITIATION, CARCINOMA, IMPACT, METAANALYSIS, ONCOLOGY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 502.61 KB

Citation

Please use this url to cite or link to this publication:

MLA
Timmermans, M., et al. “Interval between Debulking Surgery and Adjuvant Chemotherapy Is Associated with Overall Survival in Patients with Advanced Ovarian Cancer.” GYNECOLOGIC ONCOLOGY, vol. 150, no. 3, 2018, pp. 446–50.
APA
Timmermans, M., van der Aa, M., Lalisang, R., I., Witteveen, P., Van de Vijver, K., Kruitwagen, R., & Sonke, G. (2018). Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. GYNECOLOGIC ONCOLOGY, 150(3), 446–450.
Chicago author-date
Timmermans, M, MA van der Aa, R Lalisang I, PO Witteveen, Koen Van de Vijver, RF Kruitwagen, and GS Sonke. 2018. “Interval between Debulking Surgery and Adjuvant Chemotherapy Is Associated with Overall Survival in Patients with Advanced Ovarian Cancer.” GYNECOLOGIC ONCOLOGY 150 (3): 446–50.
Chicago author-date (all authors)
Timmermans, M, MA van der Aa, R Lalisang I, PO Witteveen, Koen Van de Vijver, RF Kruitwagen, and GS Sonke. 2018. “Interval between Debulking Surgery and Adjuvant Chemotherapy Is Associated with Overall Survival in Patients with Advanced Ovarian Cancer.” GYNECOLOGIC ONCOLOGY 150 (3): 446–450.
Vancouver
1.
Timmermans M, van der Aa M, Lalisang R I, Witteveen P, Van de Vijver K, Kruitwagen R, et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. GYNECOLOGIC ONCOLOGY. 2018;150(3):446–50.
IEEE
[1]
M. Timmermans et al., “Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer,” GYNECOLOGIC ONCOLOGY, vol. 150, no. 3, pp. 446–450, 2018.
@article{8576940,
  author       = {Timmermans, M and van der Aa, MA and Lalisang, R, I and Witteveen, PO and Van de Vijver, Koen and Kruitwagen, RF and Sonke, GS},
  issn         = {0090-8258},
  journal      = {GYNECOLOGIC ONCOLOGY},
  keywords     = {Epithelial ovarian cancer,Primary debulking surgery,Neoadjuvant chemotherapy,Adjuvant chemotherapy,Timing,Overall survival,TIME-INTERVAL,NEOADJUVANT CHEMOTHERAPY,PROGNOSTIC IMPORTANCE,COMORBIDITY INDEX,CLINICAL-PRACTICE,INITIATION,CARCINOMA,IMPACT,METAANALYSIS,ONCOLOGY},
  language     = {eng},
  number       = {3},
  pages        = {446--450},
  title        = {Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer},
  url          = {http://dx.doi.org/10.1016/j.ygyno.2018.07.004},
  volume       = {150},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: